Consort Medical (LON:CSRT) Rating Increased to Buy at Shore Capital

Shore Capital upgraded shares of Consort Medical (LON:CSRT) to a buy rating in a research report released on Friday morning, ThisIsMoney.Co.Uk reports.

Shares of CSRT opened at GBX 758.86 ($9.92) on Friday. The company has a debt-to-equity ratio of 46.56, a quick ratio of 1.04 and a current ratio of 1.63. The company has a market capitalization of $374.60 million and a price-to-earnings ratio of 35.80. The company’s 50 day simple moving average is GBX 751.22 and its 200 day simple moving average is GBX 827.06. Consort Medical has a 1 year low of GBX 700 ($9.15) and a 1 year high of GBX 1,210 ($15.81).

In other news, insider Chris Brinsmead acquired 1,000 shares of Consort Medical stock in a transaction that occurred on Friday, August 2nd. The shares were acquired at an average price of GBX 732 ($9.56) per share, with a total value of £7,320 ($9,564.88). Also, insider Ian James Nicholson acquired 1,350 shares of Consort Medical stock in a transaction that occurred on Friday, August 9th. The shares were purchased at an average cost of GBX 736 ($9.62) per share, for a total transaction of £9,936 ($12,983.14).

Consort Medical Company Profile

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.

See Also: How to interpret a stock’s beta number

Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with's FREE daily email newsletter.